ArticleBritish journal of cancer2003
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.Annals of oncology : official journal of the European Society for Medical Oncology · 2008Trial
- Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis.Breast (Edinburgh, Scotland) · 2026Article
- Synergistic effects of sequential treatment with doxorubicin and zoledronic acid on anticancer effects in estrogen receptor-negative breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).Breast cancer research : BCR · 2019Article
- VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.Fukushima journal of medical science · 2015Article
- Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives.Journal of clinical medicine · 2014Review
- Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Breast cancer research : BCR · 2012Review
- Direct antitumour activity of zoledronic acid: preclinical and clinical data.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Review
- Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.British journal of cancer · 2010Article
- Oral bisphosphonate use and breast cancer incidence in postmenopausal women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Article
- How do bisphosphonates inhibit bone metastasis in vivo?Neoplasia (New York, N.Y.) · 2010Article
- Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.Journal of endocrinological investigation · 2010Article
- Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.International journal of cancer · 2010Article
- Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.Cancer biology & therapy · 2009Article
- [Bisphosphonates for malignant bone tumors].Der Orthopade · 2009Review
- Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.Breast cancer research : BCR · 2008Article
- A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid.Skeletal radiology · 2007Article
- Bisphosphonates for malignancy-related bone disease: current status, future developments.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2006Review
- Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.Clinical & experimental metastasis · 2006Article
- Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.Breast cancer research : BCR · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone tissue constitutes a fertile 'soil' for metastatic tumours, notably breast cancer. High concentrations of growth factors in bone matrix favour cancer cell proliferation and survival, and a vicious cycle settles between bone matrix, osteoclasts and cancer cells. Classically, bisphosphonates interrupt this vicious cycle by inhibiting osteoclast-mediated bone resorption. We and others recently reported that bisphosphonates can also induce human breast cancer cell death in vitro, which could contribute to their beneficial clinical effects. We hypothesised that bisphosphonates could inhibit the favourable effects of 'bone-derived' growth factors, and indeed found that bisphosphonates reduced or abolished the stimulatory effects of growth factors (IGFs, FGF-2) on MCF-7 and T47D cell proliferation and inhibited their protective effects on apoptotic cell death in vitro under serum-free conditions. This could happen through an interaction with growth factors' intracellular phosphorylation transduction pathways, such as ERK1/2-MAPK. In conclusion, we report that bisphosphonates antagonised the stimulatory effects of growth factors on human breast cancer cell survival and reduced their protective effects against apoptotic cell death. Bisphosphonates and growth factors thus appear to be concurrent compounds for tumour cell growth and survival in bone tissue. This could represent a new mechanism of action of bisphosphonates in their protective effects against breast cancer-induced osteolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.